{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:23:58Z","timestamp":1786983838006,"version":"build-2736575974"},"reference-count":256,"publisher":"Elsevier","isbn-type":[{"value":"9780323994026","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.ircmb.2022.03.010","type":"book-chapter","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T08:31:29Z","timestamp":1652862689000},"page":"143-199","source":"Crossref","is-referenced-by-count":19,"title":["Emerging applications of nanobodies in cancer therapy"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.ircmb.2022.03.010_bb0010","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/s41587-020-0676-z","volume":"38","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0015","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1471-4159.2005.03463.x","article-title":"The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells","volume":"95","author":"Abulrob","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0020","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000911","article-title":"Tim-3 finds its place in the cancer immunotherapy landscape","volume":"8","author":"Acharya","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0025","doi-asserted-by":"crossref","first-page":"632687","DOI":"10.3389\/fimmu.2021.632687","article-title":"Immunogenicity risk profile of nanobodies","volume":"12","author":"Ackaert","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0030","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1089\/hum.2010.184","article-title":"Lentiviral vectors targeted to MHC II are effective in immunization","volume":"22","author":"Ageichik","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0035","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1287246","article-title":"A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform","volume":"6","author":"Albert","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0040","doi-asserted-by":"crossref","first-page":"25597","DOI":"10.18632\/oncotarget.25390","article-title":"From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo","volume":"9","author":"Albert","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0045","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jconrel.2012.11.007","article-title":"Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells","volume":"165","author":"Altintas","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0050","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1021\/acs.molpharmaceut.8b00584","article-title":"Anti-multiple myeloma activity of nanobody-based anti-CD38 chimeric antigen receptor T cells","volume":"15","author":"An","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0055","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41375-020-01065-5","article-title":"A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells","volume":"35","author":"Arvindam","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0060","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3389\/fimmu.2018.01977","article-title":"Turn back the TIMe: targeting tumor infiltrating myeloid cells to revert cancer progression","volume":"9","author":"Awad","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0065","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.omtm.2021.05.017","article-title":"Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade","volume":"22","author":"Awad","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0070","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.biopha.2017.06.025","article-title":"Identification and in vitro characterization of novel nanobodies against human granulocyte colony-stimulating factor receptor to provide inhibition of G-CSF function","volume":"93","author":"Bakherad","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0075","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/hyb.2008.0079","article-title":"Anti-MUC1 nanobody can redirect T-body cytotoxic effector function","volume":"28","author":"Bakhtiari","year":"2009","journal-title":"Hybridoma (Larchmt)"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0080","doi-asserted-by":"crossref","first-page":"107927","DOI":"10.1016\/j.intimp.2021.107927","article-title":"Liposome-based nanocarriers loaded with anthrax lethal factor and armed with anti-CD19 VHH for effectively inhibiting MAPK pathway in B cells","volume":"100","author":"Banihashemi","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0085","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3389\/fimmu.2017.01603","article-title":"Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics","volume":"8","author":"Bannas","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/biom11020238","article-title":"The application of nanobody in CAR-T therapy","volume":"11","author":"Bao","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/protein\/gzm064","article-title":"Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells","volume":"21","author":"Behar","year":"2008","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.nbt.2012.09.002","article-title":"Development of VEGFR2-specific nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth","volume":"30","author":"Behdani","year":"2013","journal-title":"N. Biotechnol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168691","article-title":"TNFalpha and immune checkpoint inhibition: friend or foe for lung cancer?","volume":"22","author":"Benoot","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0115","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2019.10.024","article-title":"Stromal-targeting radioimmunotherapy mitigates the progression of therapy-resistant tumors","volume":"314","author":"Bolli","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0125","doi-asserted-by":"crossref","first-page":"2004574","DOI":"10.1002\/advs.202004574","article-title":"Targeted repolarization of tumor-associated macrophages via imidazoquinoline-linked nanobodies","volume":"8","author":"Bolli","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0130","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/jgm.713","article-title":"Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy","volume":"7","author":"Bonehill","year":"2005","journal-title":"J. Gene Med."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0135","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1084\/jem.20032220","article-title":"In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination","volume":"199","author":"Bonifaz","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0140","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3389\/fimmu.2019.00294","article-title":"Combination of synthetic long peptides and XCL1 fusion proteins results in superior tumor control","volume":"10","author":"Botelho","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0145","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/vaccines7030085","article-title":"Single domain antibody-mediated blockade of programmed death-ligand 1 on dendritic cells enhances CD8 T-cell activation and cytokine production","volume":"7","author":"Broos","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0150","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/cancers11060872","article-title":"Evaluating a single domain antibody targeting human PD-L1 as a nuclear imaging and therapeutic agent","volume":"11","author":"Broos","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0155","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1053\/j.seminoncol.2014.08.005","article-title":"From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies","volume":"41","author":"Caruana","year":"2014","journal-title":"Semin. Oncol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0160","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1398876","article-title":"A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment","volume":"7","author":"Cauwels","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0165","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1158\/0008-5472.CAN-17-1980","article-title":"Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments","volume":"78","author":"Cauwels","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0170","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719841581","article-title":"CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products","volume":"10","author":"Chavez","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101644","article-title":"Immunization of mice with lentiviral vectors targeted to MHC class II+ cells is due to preferential transduction of dendritic cells in vivo","volume":"9","author":"Cire","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0180","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1038\/s41467-018-07195-w","article-title":"A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity","volume":"9","author":"Compte","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0185","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1158\/0008-5472.CAN-03-3935","article-title":"Efficient cancer therapy with a nanobody-based conjugate","volume":"64","author":"Cortez-Retamozo","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0190","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrc3670","article-title":"Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy","volume":"14","author":"Coulie","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0195","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2019.37.15_suppl.2554","article-title":"Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1\/CTLA4) from a first-in-human study in subjects with advanced solid tumors","volume":"37","author":"Coward","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0200","doi-asserted-by":"crossref","first-page":"190235","DOI":"10.1098\/rsob.190235","article-title":"Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH","volume":"10","author":"Crowley","year":"2020","journal-title":"Open Biol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0205","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jconrel.2014.07.040","article-title":"Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study","volume":"192","author":"Cruz","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0210","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2967\/jnumed.120.246041","article-title":"Immune-checkpoint blockade enhances (225)Ac-PSMA617 efficacy in a mouse model of prostate cancer","volume":"62","author":"Czernin","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0215","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3389\/fphar.2019.00510","article-title":"Emerging fluorescent molecular tracers to guide intra-operative surgical decision-making","volume":"10","author":"Debie","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0220","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/acs.molpharmaceut.6b01053","article-title":"Effect of dye and conjugation chemistry on the biodistribution profile of near-infrared-labeled nanobodies as tracers for image-guided surgery","volume":"14","author":"Debie","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0225","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11307-017-1134-2","article-title":"Improved debulking of peritoneal tumor implants by near-infrared fluorescent nanobody image guidance in an experimental mouse model","volume":"20","author":"Debie","year":"2018","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0230","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2019.11.014","article-title":"Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours","volume":"317","author":"Debie","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0235","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/biom11030360","article-title":"The design and preclinical evaluation of a single-label bimodal nanobody tracer for image-guided surgery","volume":"11","author":"Debie","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0240","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.7150\/thno.37949","article-title":"Acute cellular and vascular responses to photodynamic therapy using EGFR-targeted nanobody-photosensitizer conjugates studied with intravital optical imaging and magnetic resonance imaging","volume":"10","author":"de Bruijn","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0245","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.clim.2016.06.012","article-title":"Highly specific and potently activating Vgamma9Vdelta2-T cell specific nanobodies for diagnostic and therapeutic applications","volume":"169","author":"de Bruin","year":"2016","journal-title":"Clin. Immunol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0250","article-title":"A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vgamma9Vdelta2-T cells","volume":"7","author":"de Bruin","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0255","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/eji.202048992","article-title":"Regulatory T cell targeting in cancer: emerging strategies in immunotherapy","volume":"51","author":"Dees","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0260","doi-asserted-by":"crossref","first-page":"782","DOI":"10.2967\/jnumed.109.070078","article-title":"Nanobodies as tools for in vivo imaging of specific immune cell types","volume":"51","author":"De Groeve","year":"2010","journal-title":"J. Nucl. Med."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0265","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1021\/acs.molpharmaceut.9b00360","article-title":"Nanobody-targeted photodynamic therapy selectively kills viral GPCR-expressing glioblastoma cells","volume":"16","author":"De Groof","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0270","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1021\/acs.molpharmaceut.9b00354","article-title":"Labeling of anti-HER2 nanobodies with astatine-211: optimization and the effect of different coupling reagents on their in vivo behavior","volume":"16","author":"Dekempeneer","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0275","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1021\/acs.molpharmaceut.0c00580","article-title":"Therapeutic efficacy of (213)Bi-labeled sdAbs in a preclinical model of ovarian cancer","volume":"17","author":"Dekempeneer","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0280","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jconrel.2020.04.030","article-title":"Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session","volume":"323","author":"Deken","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0285","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3390\/ijms19020403","article-title":"Nanobody based dual specific CARs","volume":"19","author":"De Munter","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0290","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3390\/ijms21030883","article-title":"Rapid and effective generation of nanobody based CARs using PCR and Gibson assembly","volume":"21","author":"De Munter","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0295","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000200","article-title":"A bispecific antibody based on pertuzumab Fab has potent antitumor activity","volume":"41","author":"Deng","year":"2018","journal-title":"J. Immunother."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0305","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3389\/fimmu.2017.00884","article-title":"Neutralization of human interleukin 23 by multivalent nanobodies explained by the structure of cytokine-nanobody complex","volume":"8","author":"Desmyter","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0310","doi-asserted-by":"crossref","first-page":"2000699","DOI":"10.1080\/2162402X.2021.2000699","article-title":"CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma","volume":"10","author":"De Veirman","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0315","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jconrel.2019.02.023","article-title":"Single-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages","volume":"299","author":"De Vlaeminck","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0320","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.3390\/cancers12123582","article-title":"Targeting neuropilin-1 with nanobodies reduces colorectal carcinoma development","volume":"12","author":"De Vlaeminck","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0325","doi-asserted-by":"crossref","first-page":"232ra251","DOI":"10.1126\/scitranslmed.3008068","article-title":"Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205","volume":"6","author":"Dhodapkar","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0330","doi-asserted-by":"crossref","first-page":"708","DOI":"10.7150\/thno.8156","article-title":"Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody","volume":"4","author":"D'Huyvetter","year":"2014","journal-title":"Theranostics"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0335","doi-asserted-by":"crossref","first-page":"6616","DOI":"10.1158\/1078-0432.CCR-17-0310","article-title":"(131)I-labeled anti-HER2 camelid sdAb as a theranostic tool in cancer treatment","volume":"23","author":"D'Huyvetter","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0340","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2967\/jnumed.120.255679","article-title":"Phase I trial of (131)I-GMIB-anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients","volume":"62","author":"D'Huyvetter","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0345","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/15384047.2016.1139266","article-title":"A novel bispecific antibody, BiSS, with potent anti-cancer activities","volume":"17","author":"Dong","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0350","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/imr.12131","article-title":"Design and development of therapies using chimeric antigen receptor-expressing T cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol. Rev."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0355","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/2326-6066.CIR-17-0495","article-title":"Targeting cytokine therapy to the pancreatic tumor microenvironment using PD-L1-specific VHHs","volume":"6","author":"Dougan","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0360","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13045-021-01171-6","article-title":"A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma","volume":"14","author":"Duray","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0365","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0370","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2011.07.031","article-title":"Albumin-based nanoparticles as potential controlled release drug delivery systems","volume":"157","author":"Elzoghby","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0375","first-page":"3183","article-title":"Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms","volume":"46","author":"Epenetos","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0380","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1158\/2326-6066.CIR-19-0837","article-title":"Potent cytolytic activity and specific IL15 delivery in a second-generation trispecific killer engager","volume":"8","author":"Felices","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0385","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1089\/hum.2008.189","article-title":"Single-chain antibodies that target lentiviral vectors to MHC class II on antigen-presenting cells","volume":"20","author":"Gennari","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0390","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4236\/abb.2013.44A011","article-title":"Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments","volume":"4","author":"Gil","year":"2013","journal-title":"Adv. Biosci. Biotechnol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0395","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S1470-2045(17)30379-0","article-title":"Targeted radionuclide therapy in combined-modality regimens","volume":"18","author":"Gill","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0400","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2014BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0405","article-title":"Nanobody-engineered natural killer cell conjugates for solid tumor adoptive immunotherapy","volume":"17","author":"Gong","year":"2021","journal-title":"Small"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0410","doi-asserted-by":"crossref","first-page":"785634","DOI":"10.1155\/2015\/785634","article-title":"Pros and cons of antigen-presenting cell targeted tumor vaccines","volume":"2015","author":"Goyvaerts","year":"2015","journal-title":"J. Immunol. Res."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0415","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/gt.2011.206","article-title":"Development of the nanobody display technology to target lentiviral vectors to antigen-presenting cells","volume":"19","author":"Goyvaerts","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0420","doi-asserted-by":"crossref","first-page":"11304","DOI":"10.1128\/JVI.01498-13","article-title":"Targeting of human antigen-presenting cell subsets","volume":"87","author":"Goyvaerts","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0425","doi-asserted-by":"crossref","first-page":"704","DOI":"10.18632\/oncotarget.1680","article-title":"Immunogenicity of targeted lentivectors","volume":"5","author":"Goyvaerts","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0430","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/gt.2017.30","article-title":"Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery","volume":"24","author":"Goyvaerts","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0435","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/ijms17010033","article-title":"Targeted radionuclide therapy of human tumors","volume":"17","author":"Gudkov","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0440","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0445","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1172\/JCI66776","article-title":"Macrophages eliminate circulating tumor cells after monoclonal antibody therapy","volume":"124","author":"Gul","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0450","doi-asserted-by":"crossref","first-page":"eaax0876","DOI":"10.1126\/scitranslmed.aax0876","article-title":"Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies","volume":"12","author":"Gurbatri","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0455","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/iub.2019","article-title":"T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy","volume":"71","author":"Hajari Taheri","year":"2019","journal-title":"IUBMB Life"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0460","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/cells9020321","article-title":"Targeting CD38-expressing multiple myeloma and Burkitt lymphoma cells in vitro with nanobody-based chimeric antigen receptors (Nb-CARs)","volume":"9","author":"Hambach","year":"2020","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0465","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0470","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.2019.37.15_suppl.2535","article-title":"The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain","volume":"37","author":"Han","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0475","doi-asserted-by":"crossref","first-page":"e000927","DOI":"10.1136\/jitc-2020-000927","article-title":"Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus","volume":"8","author":"Han","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0480","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/med.21818","article-title":"The antigen-binding moiety in the driver's seat of CARs","volume":"42","author":"Hanssens","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0485","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0490","article-title":"ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy","volume":"7","author":"Harwood","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0495","doi-asserted-by":"crossref","first-page":"10787","DOI":"10.1002\/jcb.28370","article-title":"Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer","volume":"120","author":"Hassani","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0500","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.2019002779","article-title":"Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia","volume":"135","author":"He","year":"2020","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0505","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/protein\/gzw043","article-title":"Isolation of TGF-beta-neutralizing single-domain antibodies of predetermined epitope specificity using next-generation DNA sequencing","volume":"29","author":"Henry","year":"2016","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0510","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1016\/S1470-2045(19)30317-1","article-title":"Latest developments in molecular tracers for fluorescence image-guided cancer surgery","volume":"20","author":"Hernot","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0515","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.nano.2013.12.007","article-title":"Nanobody-photosensitizer conjugates for targeted photodynamic therapy","volume":"10","author":"Heukers","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0520","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/hed.23110","article-title":"Surgical margins in head and neck cancer: a contemporary review","volume":"35","author":"Hinni","year":"2013","journal-title":"Head Neck"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0525","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1395127","article-title":"Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)","volume":"7","author":"Hoffmann","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0530","first-page":"1201","article-title":"Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3)","volume":"19","author":"Homayouni","year":"2016","journal-title":"Iran. J. Basic Med. Sci."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0535","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.4049\/jimmunol.1203195","article-title":"Transmembrane TNF-alpha promotes suppressive activities of myeloid-derived suppressor cells via TNFR2","volume":"192","author":"Hu","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0540","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3389\/fimmu.2017.01442","article-title":"Nanobody-based delivery systems for diagnosis and targeted tumor therapy","volume":"8","author":"Hu","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0545","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1249561","article-title":"Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer","volume":"6","author":"Huang","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0550","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.4161\/19420862.2014.975099","article-title":"Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction","volume":"6","author":"Huet","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0555","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911223","article-title":"Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies","volume":"12","author":"Huyghe","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0560","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1073\/pnas.69.9.2659","article-title":"Localization of antibody-combining sites within the variable portions of heavy and light chains","volume":"69","author":"Inbar","year":"1972","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0565","doi-asserted-by":"crossref","first-page":"10184","DOI":"10.1073\/pnas.1710776114","article-title":"Localized CD47 blockade enhances immunotherapy for murine melanoma","volume":"114","author":"Ingram","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0570","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41467-017-00799-8","article-title":"PD-L1 is an activation-independent marker of brown adipocytes","volume":"8","author":"Ingram","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0575","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1073\/pnas.1801524115","article-title":"Anti-CTLA-4 therapy requires an Fc domain for efficacy","volume":"115","author":"Ingram","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0580","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.yexcr.2011.08.015","article-title":"Nanobody-based chimeric receptor gene integration in Jurkat cells mediated by phiC31 integrase","volume":"317","author":"Iri-Sofla","year":"2011","journal-title":"Exp. Cell Res."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0585","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/imr.12774","article-title":"Updates on CAR T-cell therapy in B-cell malignancies","volume":"290","author":"Jacoby","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0590","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.bbagen.2013.09.029","article-title":"T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy","volume":"1840","author":"Jamnani","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0595","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.canlet.2016.10.031","article-title":"Neutralization of TNFalpha in tumor with a novel nanobody potentiates paclitaxel-therapy and inhibits metastasis in breast cancer","volume":"386","author":"Ji","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0600","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/1078-0432.CCR-20-0245","article-title":"The changing landscape of therapeutic cancer vaccines-novel platforms and neoantigen identification","volume":"27","author":"Jou","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0605","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/ph13090245","article-title":"Antibody-drug conjugates: the last decade","volume":"13","author":"Joubert","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0610","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The therapeutic potential of nanobodies","volume":"34","author":"Jov\u010devska","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0615","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0620","first-page":"5144","article-title":"Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier","volume":"52","author":"Juweid","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0625","first-page":"1","article-title":"Boosting therapeutic potency of antibodies by taming Fc domain functions","volume":"51","author":"Kang","year":"2019","journal-title":"Exp. Mol. Med."},{"issue":"Suppl. 1","key":"10.1016\/bs.ircmb.2022.03.010_bb0630","first-page":"4S","article-title":"Radiobiologic principles in radionuclide therapy","volume":"46","author":"Kassis","year":"2005","journal-title":"J. Nucl. Med."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0635","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s12185-012-1037-6","article-title":"A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells","volume":"95","author":"Khaleghi","year":"2012","journal-title":"Int. J. Hematol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0640","doi-asserted-by":"crossref","first-page":"e001292","DOI":"10.1136\/jitc-2020-001292","article-title":"Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy","volume":"9","author":"Khalique","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0645","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1007\/s00259-013-2471-2","article-title":"Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery","volume":"40","author":"Kijanka","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0650","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13550-016-0166-y","article-title":"Optical imaging of pre-invasive breast cancer with a combination of VHHs targeting CAIX and HER2 increases contrast and facilitates tumour characterization","volume":"6","author":"Kijanka","year":"2016","journal-title":"EJNMMI Res."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0655","doi-asserted-by":"crossref","first-page":"eabe8671","DOI":"10.1126\/sciadv.abe8671","article-title":"Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers","volume":"7","author":"Kitamura","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0660","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1158\/1535-7163.MCT-17-0554","article-title":"Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma","volume":"16","author":"Krasniqi","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0665","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ncpuro1121","article-title":"Importance of surgical margins in the management of renal cell carcinoma","volume":"5","author":"Lam","year":"2008","journal-title":"Nat. Clin. Pract. Urol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0670","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","article-title":"Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains","volume":"11","author":"Lam","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0675","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S1470-2045(20)30600-8","article-title":"Real-time fluorescence imaging in intraoperative decision making for cancer surgery","volume":"22","author":"Lauwerends","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0680","doi-asserted-by":"crossref","first-page":"7772","DOI":"10.7150\/thno.34941","article-title":"Theranostics in immuno-oncology using nanobody derivatives","volume":"9","author":"Lecocq","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0685","doi-asserted-by":"crossref","DOI":"10.3390\/biom9100548","article-title":"Noninvasive imaging of the immune checkpoint LAG-3 using nanobodies, from development to pre-clinical use","volume":"9","author":"Lecocq","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0690","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/ijms22010075","article-title":"The next-generation immune checkpoint LAG-3 and its therapeutic potential in oncology: third time's a charm","volume":"22","author":"Lecocq","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0695","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2967\/jnumed.120.258871","article-title":"Single-domain antibody nuclear imaging allows noninvasive quantification of LAG-3 expression by tumor-infiltrating leukocytes and predicts response of immune checkpoint blockade","volume":"62","author":"Lecocq","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0700","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13550-021-00857-9","article-title":"Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer","volume":"11","author":"Lecocq","year":"2021","journal-title":"EJNMMI Res."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0705","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/leu.2013.292","article-title":"Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic nanobodies","volume":"28","author":"Lemaire","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0710","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/CJI.0000000000000099","article-title":"A novel bispecific antibody, S-Fab, induces potent cancer cell killing","volume":"38","author":"Li","year":"2015","journal-title":"J. Immunother."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0715","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13568-016-0201-4","article-title":"A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells","volume":"6","author":"Li","year":"2016","journal-title":"AMB Express"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0720","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1080\/15384047.2016.1235659","article-title":"Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity","volume":"17","author":"Li","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0725","first-page":"E6623","article-title":"Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma","volume":"114","author":"Li","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0730","article-title":"Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells","volume":"13","author":"Li","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0735","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-021-01095-1","article-title":"Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\/microsatellite instability high solid tumors","volume":"14","author":"Li","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0740","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.2147\/DDDT.S166373","article-title":"A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities","volume":"12","author":"Liu","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0745","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/s41419-020-03161-x","article-title":"Tumor necrosis factor alpha inhibition overcomes immunosuppressive M2b macrophage-induced bevacizumab resistance in triple-negative breast cancer","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0750","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0755","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/antib7010010","article-title":"Factors affecting the pharmacology of antibody-drug conjugates","volume":"7","author":"Lucas","year":"2018","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0760","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.surg.2020.02.020","article-title":"Tumor-specific near-infrared nanobody probe rapidly labels tumors in an orthotopic mouse model of pancreatic cancer","volume":"168","author":"Lwin","year":"2020","journal-title":"Surgery"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0765","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/jso.26623","article-title":"Rapid tumor-labeling kinetics with a site-specific near-infrared anti-CEA nanobody in a patient-derived orthotopic xenograft mouse model of colon cancer","volume":"124","author":"Lwin","year":"2021","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0770","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.bbrc.2020.07.072","article-title":"A novel bispecific nanobody with PD-L1\/TIGIT dual immune checkpoint blockade","volume":"531","author":"Ma","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0775","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12951-020-0571-2","article-title":"Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential","volume":"18","author":"Ma","year":"2020","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0780","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2016.6","article-title":"Targeting dendritic cells: a promising strategy to improve vaccine effectiveness","volume":"5","author":"Macri","year":"2016","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0785","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-136307","article-title":"CARTITUDE-1: phase 1b\/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed\/refractory multiple myeloma","volume":"136","author":"Madduri","year":"2020","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0790","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4161\/mabs.22775","article-title":"Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells","volume":"5","author":"Marcucci","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0795","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1021\/bc500111t","article-title":"Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging","volume":"25","author":"Massa","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0800","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/cmmi.1696","article-title":"Sortase A-mediated site-specific labeling of camelid single-domain antibody-fragments: a versatile strategy for multiple molecular imaging modalities","volume":"11","author":"Massa","year":"2016","journal-title":"Contrast Media Mol. Imaging"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0805","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3389\/fimmu.2019.01791","article-title":"Carcinoembryonic antigen (CEA)-specific 4-1BB-costimulation induced by CEA-targeted 4-1BB-agonistic trimerbodies","volume":"10","author":"Mikkelsen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0810","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.3389\/fimmu.2019.02836","article-title":"Harnessing NK cells for cancer treatment","volume":"10","author":"Minetto","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0815","doi-asserted-by":"crossref","first-page":"8910","DOI":"10.3390\/ijms22168910","article-title":"Strategies to improve the antitumor effect of \u03b3\u03b4 T cell immunotherapy for clinical application","volume":"22","author":"Miyashita","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0820","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1126\/science.147.3660.873","article-title":"Contact-induced cytotoxicity by lymphoid cells containing foreign isoantigens","volume":"147","author":"Moeller","year":"1965","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0825","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00262-018-2181-5","article-title":"Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies","volume":"67","author":"Molgaard","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0830","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.3389\/fimmu.2019.01818","article-title":"The TNF paradox in cancer progression and immunotherapy","volume":"10","author":"Montfort","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0835","doi-asserted-by":"crossref","first-page":"15517","DOI":"10.1038\/s41598-021-93972-5","article-title":"PE38-based gene therapy of HER2-positive breast cancer stem cells via VHH-redirected polyamidoamine dendrimers","volume":"11","author":"Moradian","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0840","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1158\/0008-5472.CAN-11-2994","article-title":"Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages","volume":"72","author":"Movahedi","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0845","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1023\/A:1016064930502","article-title":"Albumin nanospheres as carriers for passive drug targeting: an optimized manufacturing technique","volume":"13","author":"Muller","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0850","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0855","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fonc.2017.00314","article-title":"Fluorescence-guided surgery","volume":"7","author":"Nagaya","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0860","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0865","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/jso.24047","article-title":"The importance of surgical margins in breast cancer","volume":"113","author":"O'Kelly Priddy","year":"2016","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0870","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2010.03.020","article-title":"Downregulation of EGFR by a novel multivalent nanobody-liposome platform","volume":"145","author":"Oliveira","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0875","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2310\/7290.2011.00025","article-title":"Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody","volume":"11","author":"Oliveira","year":"2012","journal-title":"Mol. Imaging"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0880","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1038\/s41598-018-23403-5","article-title":"Positive surgical margins in the 10 most common solid cancers","volume":"8","author":"Orosco","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0885","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.2147\/IJN.S164542","article-title":"Site-specific PEGylation of an anti-CEA\/CD3 bispecific antibody improves its antitumor efficacy","volume":"13","author":"Pan","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0890","doi-asserted-by":"crossref","first-page":"e1514","DOI":"10.1002\/onco.13817","article-title":"First-in-human phase I study of envafolimab, a novel subcutaneous single-domain anti-PD-L1 antibody, in patients with advanced solid tumors","volume":"26","author":"Papadopoulos","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0895","doi-asserted-by":"crossref","first-page":"261","DOI":"10.21037\/atm.2016.04.01","article-title":"Harnessing the immune system to improve cancer therapy","volume":"4","author":"Papaioannou","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0900","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0905","doi-asserted-by":"crossref","first-page":"627932","DOI":"10.3389\/fimmu.2021.627932","article-title":"Cancer vaccines, adjuvants, and delivery systems","volume":"12","author":"Paston","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0910","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0915","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1021\/ja01867a018","article-title":"A theory of the structure and process of formation of antibodies","volume":"62","author":"Pauling","year":"1940","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0920","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/s41551-021-00738-5","article-title":"Induction of antigen-specific tolerance by nanobody-antigen adducts that target class-II major histocompatibility complexes","volume":"5","author":"Pishesha","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0925","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.11349","article-title":"Nanobodies: site-specific labeling for super-resolution imaging, rapid epitope-mapping and native protein complex isolation","volume":"4","author":"Pleiner","year":"2015","journal-title":"Elife"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0930","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1042\/bj0730119","article-title":"The hydrolysis of rabbit y-globulin and antibodies with crystalline papain","volume":"73","author":"Porter","year":"1959","journal-title":"Biochem. J."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0935","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrclinonc.2011.160","article-title":"Clinical radioimmunotherapy\u2014the role of radiobiology","volume":"8","author":"Pouget","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0940","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1021\/acs.molpharmaceut.7b00985","article-title":"Evaluation of an anti-HER2 nanobody labeled with (225)Ac for targeted alpha-particle therapy of cancer","volume":"15","author":"Pruszynski","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0945","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12041017","article-title":"Preclinical targeted alpha- and beta(-)-radionuclide therapy in HER2-positive brain metastasis using camelid single-domain antibodies","volume":"12","author":"Puttemans","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0950","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1158\/1535-7163.MCT-21-0220","article-title":"The road to personalized myeloma medicine: patient-specific single-domain antibodies for anti-idiotypic radionuclide therapy","volume":"21","author":"Puttemans","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0955","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0960","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.addr.2019.04.006","article-title":"CAR T-cell bioengineering: single variable domain of heavy chain antibody targeted CARs","volume":"141","author":"Rahbarizadeh","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0965","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030428","article-title":"Site-specific dual-labeling of a VHH with a chelator and a photosensitizer for nuclear imaging and targeted photodynamic therapy of EGFR-positive tumors","volume":"13","author":"Renard","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0970","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/08830189709045707","article-title":"Fc receptors as targets for immunotherapy","volume":"16","author":"Rouard","year":"1997","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0975","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1158\/1535-7163.MCT-12-1012","article-title":"Single-domain antibody-based and linker-free bispecific antibodies targeting FcgammaRIII induce potent antitumor activity without recruiting regulatory T cells","volume":"12","author":"Rozan","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0980","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.3390\/ijms20194818","article-title":"Identification of new DR5 agonistic nanobodies and generation of multivalent nanobody constructs for cancer treatment","volume":"20","author":"Sadeghnezhad","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0985","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1146\/annurev-cancerbio-050216-034351","article-title":"Chimeric antigen receptors: a paradigm shift in immunotherapy","volume":"1","author":"Sadelain","year":"2017","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0990","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb0995","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1000","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2012.08.010","article-title":"Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents","volume":"334","author":"Sharifzadeh","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41417-017-0002-1","article-title":"Development of an adenovirus vector vaccine platform for targeting dendritic cells","volume":"25","author":"Sharma","year":"2018","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1010","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.3390\/ijms21103525","article-title":"CARs: beyond T cells and T cell-derived signaling domains","volume":"21","author":"Sievers","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1015","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3390\/biomedicines8120562","article-title":"Long-term systemic expression of a novel PD-1 blocking nanobody from an AAV vector provides antitumor activity without toxicity","volume":"8","author":"Silva-Pilipich","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1020","doi-asserted-by":"crossref","first-page":"E2646","DOI":"10.1073\/pnas.1604268113","article-title":"Durable antitumor responses to CD47 blockade require adaptive immune stimulation","volume":"113","author":"Sockolosky","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1025","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/jcb.25496","article-title":"TGF-beta signaling in cancer","volume":"117","author":"Syed","year":"2016","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1030","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jconrel.2011.01.015","article-title":"Nanobody-shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting","volume":"151","author":"Talelli","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1035","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.biomaterials.2012.09.064","article-title":"Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy","volume":"34","author":"Talelli","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1040","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1166\/jbn.2019.2859","article-title":"A nanobody against cytotoxic T-lymphocyte associated antigen-4 increases the anti-tumor effects of specific CD8(+) T cells","volume":"15","author":"Tang","year":"2019","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1045","doi-asserted-by":"crossref","first-page":"8328","DOI":"10.1073\/pnas.1003251107","article-title":"IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis","volume":"107","author":"Teng","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1050","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1158\/0008-5472.CAN-10-3994","article-title":"Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastases","volume":"71","author":"Teng","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1055","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.3390\/cancers13215446","article-title":"Enhancement of NK cell antitumor effector functions using a bispecific single domain antibody targeting CD16 and the epidermal growth factor receptor","volume":"13","author":"Toffoli","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1060","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.18632\/oncotarget.2093","article-title":"A FcgammaRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy","volume":"5","author":"Turini","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1065","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3390\/cancers12092659","article-title":"NK-cell-mediated targeting of various solid tumors using a B7-H3 tri-specific killer engager in vitro and in vivo","volume":"12","author":"Vallera","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1070","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.3390\/cancers13163994","article-title":"A HER2 tri-specific NK cell engager mediates efficient targeting of human ovarian cancer","volume":"13","author":"Vallera","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1075","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s11307-015-0909-6","article-title":"Hypoxia-targeting fluorescent nanobodies for optical molecular imaging of pre-invasive breast cancer","volume":"18","author":"van Brussel","year":"2016","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1080","doi-asserted-by":"crossref","first-page":"e001749","DOI":"10.1136\/jitc-2020-001749","article-title":"Therapeutic depletion of CCR8(+) tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy","volume":"9","author":"Van Damme","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1085","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41541-020-00211-5","article-title":"Specific targeting of IL-1beta activity to CD8(+) T cells allows for safe use as a vaccine adjuvant","volume":"5","author":"Van Den Eeckhout","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1090","doi-asserted-by":"crossref","first-page":"e003293","DOI":"10.1136\/jitc-2021-003293","article-title":"Selective IL-1 activity on CD8(+) T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication","volume":"9","author":"Van Den Eeckhout","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1095","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"254","author":"van der Bruggen","year":"1991","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1100","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jconrel.2011.12.027","article-title":"Tumor-targeted nanobullets: anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment","volume":"159","author":"van der Meel","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1105","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1021\/mp400212v","article-title":"Inhibition of tumor growth by targeted anti-EGFR\/IGF-1R nanobullets depends on efficient blocking of cell survival pathways","volume":"10","author":"van der Meel","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1110","doi-asserted-by":"crossref","first-page":"16642","DOI":"10.1073\/pnas.1202832109","article-title":"Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects","volume":"109","author":"van de Water","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1115","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1002\/ijc.28601","article-title":"Intraoperative fluorescence delineation of head and neck cancer with a fluorescent anti-epidermal growth factor receptor nanobody","volume":"134","author":"van Driel","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1120","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2016.03.014","article-title":"EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer","volume":"229","author":"van Driel","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1125","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1021\/acs.molpharmaceut.1c00208","article-title":"Incorporation of a novel CD16-specific single-domain antibody into multispecific natural killer cell engagers with potent ADCC","volume":"18","author":"van Faassen","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1130","doi-asserted-by":"crossref","first-page":"20150797","DOI":"10.1259\/bjr.20150797","article-title":"Hybrid surgical guidance based on the integration of radionuclear and optical technologies","volume":"89","author":"van Leeuwen","year":"2016","journal-title":"Br. J. Radiol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1135","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1096\/fj.10-180331","article-title":"Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer","volume":"25","author":"Vaneycken","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1140","doi-asserted-by":"crossref","first-page":"101425","DOI":"10.1016\/j.smim.2020.101425","article-title":"Nanobodies in cancer","volume":"52","author":"Verhaar","year":"2021","journal-title":"Semin. Immunol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1145","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3389\/fimmu.2019.00008","article-title":"Vaccine strategies to improve anti-cancer cellular immune responses","volume":"10","author":"Vermaelen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1150","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1074\/jbc.M806889200","article-title":"General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold","volume":"284","author":"Vincke","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1155","first-page":"511","article-title":"Screening and antitumor effect of an antiCTLA4 nanobody","volume":"39","author":"Wan","year":"2018","journal-title":"Oncol. Rep."},{"issue":"137","key":"10.1016\/bs.ircmb.2022.03.010_bb1160","first-page":"57588","article-title":"A GPC3-targeting bispecific antibody, GPC3-S-Fab, with potent cytotoxicity","author":"Wang","year":"2018","journal-title":"J. Vis. Exp."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1165","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/s12935-021-02151-z","article-title":"Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells","volume":"21","author":"Wang","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1170","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/10826068.2019.1692217","article-title":"Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)\/PD-1 ligand 1 (PD-1\/PD-L1)","volume":"50","author":"Wen","year":"2020","journal-title":"Prep. Biochem. Biotechnol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1175","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.3389\/fimmu.2017.01848","article-title":"Neoantigen targeting-dawn of a new era in cancer immunotherapy?","volume":"8","author":"Wirth","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1180","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","article-title":"Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma","volume":"21","author":"Witzig","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1185","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1158\/2326-6066.CIR-17-0661","article-title":"Nanobody-antigen conjugates elicit HPV-specific antitumor immune responses","volume":"6","author":"Woodham","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1190","doi-asserted-by":"crossref","first-page":"9344","DOI":"10.1039\/D0CC03396K","article-title":"Clustered nanobody-drug conjugates for targeted cancer therapy","volume":"56","author":"Wu","year":"2020","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1195","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bbrc.2019.08.160","article-title":"Blocking the PD-1-PD-L1 axis by a novel PD-1 specific nanobody expressed in yeast as a potential therapeutic for immunotherapy","volume":"519","author":"Xian","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1200","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1073\/pnas.1817147116","article-title":"Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice","volume":"116","author":"Xie","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1205","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1158\/2326-6066.CIR-19-0734","article-title":"Improved antitumor efficacy of chimeric antigen receptor T cells that secrete single-domain antibody fragments","volume":"8","author":"Xie","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1210","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1215","doi-asserted-by":"crossref","first-page":"a028530","DOI":"10.1101\/cshperspect.a028530","article-title":"Interleukin (IL)-12 and IL-23 and their conflicting roles in cancer","volume":"10","author":"Yan","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1220","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3389\/fonc.2020.01182","article-title":"Nanobodies: next generation of cancer diagnostics and therapeutics","volume":"10","author":"Yang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1225","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.3389\/fimmu.2017.01860","article-title":"Engineering of Fc fragments with optimized physicochemical properties implying improvement of clinical potentials for Fc-based therapeutics","volume":"8","author":"Yang","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1230","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2013.07.039","article-title":"Positive surgical margins after radical prostatectomy: a systematic review and contemporary update","volume":"65","author":"Yossepowitch","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1235","first-page":"64","article-title":"A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia","volume":"9","author":"You","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1240","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.2147\/IJN.S127575","article-title":"Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential","volume":"12","author":"Yu","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1245","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/antib9030034","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1250","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1172\/JCI96791","article-title":"Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy","volume":"128","author":"Zeng","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1255","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002131","article-title":"Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer","volume":"9","author":"Zhai","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1260","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1038\/srep03571","article-title":"Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor","volume":"4","author":"Zhang","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1265","doi-asserted-by":"crossref","first-page":"17004","DOI":"10.1038\/celldisc.2017.4","article-title":"Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade","volume":"3","author":"Zhang","year":"2017","journal-title":"Cell Discov."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1270","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1172\/JCI64115","article-title":"TNF signaling drives myeloid-derived suppressor cell accumulation","volume":"122","author":"Zhao","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1275","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1280","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190297","article-title":"The role of interleukin-17 in tumor development and progression","volume":"217","author":"Zhao","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.ircmb.2022.03.010_bb1285","doi-asserted-by":"crossref","first-page":"2454907","DOI":"10.1155\/2020\/2454907","article-title":"Single-domain antibody-based TCR-like CAR-T: a potential cancer therapy","volume":"2020","author":"Zhu","year":"2020","journal-title":"J. Immunol. Res."}],"container-title":["International Review of Cell and Molecular Biology","New Antibody Formats"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644822000314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644822000314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T13:41:23Z","timestamp":1753278083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644822000314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323994026"],"references-count":256,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2022.03.010","relation":{},"ISSN":["1937-6448"],"issn-type":[{"value":"1937-6448","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}